Share Price and Basic Stock Data
Last Updated: October 18, 2025, 4:41 pm
| PEG Ratio | 0.32 |
|---|
Analyst Insight & Comprehensive Analysis
Bliss GVS Pharma Ltd, trading at ₹151 with a MarketCap of ₹1,589 Cr, presents an intriguing investment opportunity. With a P/E ratio of 14.9, below the industry average of 20, and a healthy ROE of 8.36%, slightly above the sector norm, the company showcases profitability and efficient use of shareholder funds. Furthermore, the ROCE of 11.7% highlights effective capital deployment, outperforming many peers in the pharmaceutical sector. The firm’s comfortable OPM of 20% indicates strong operational efficiency, a key strength that could drive sustained growth.However, with a high CCC of 246 days, significantly above the industry benchmark of 90 days, the company faces a liquidity risk that might hinder its short-term financial health. Additionally, the relatively high borrowings of ₹88 Cr could lead to increased interest costs, impacting profitability. Looking ahead, a scenario where Bliss GVS Pharma Ltd focuses on optimizing its working capital cycle and reducing debt levels could significantly enhance its financial position and mitigate these risks, potentially unlocking greater shareholder value in the long term.In conclusion, while Bliss GVS Pharma Ltd exhibits solid fundamentals and operational efficiency, addressing liquidity concerns and managing debt levels will be crucial for sustaining its growth trajectory. Investors should closely monitor the company’s efforts in improving working capital management and debt reduction to gauge its ability to navigate potential challenges and capitalize on future opportunities in the competitive pharmaceutical landscape.Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Bliss GVS Pharma Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 148 Cr. | 117 | 247/84.3 | 33.6 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.96 Cr. | 2.07 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,702 Cr. | 432 | 440/192 | 105 | 22.8 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 36.4 Cr. | 49.0 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 30.0 Cr. | 20.4 | 29.1/17.0 | 31.2 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,828.94 Cr | 1,185.68 | 50.47 | 194.07 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 189 | 172 | 206 | 185 | 160 | 212 | 201 | 198 | 184 | 218 | 210 | 198 | 207 |
| Expenses | 150 | 148 | 158 | 179 | 135 | 158 | 157 | 170 | 149 | 176 | 181 | 177 | 166 |
| Operating Profit | 39 | 25 | 48 | 6 | 24 | 54 | 44 | 28 | 34 | 41 | 30 | 21 | 41 |
| OPM % | 21% | 14% | 23% | 3% | 15% | 26% | 22% | 14% | 19% | 19% | 14% | 11% | 20% |
| Other Income | 7 | 2 | 6 | 3 | 5 | 13 | 5 | -24 | 4 | 5 | 15 | 12 | 35 |
| Interest | 2 | 2 | 1 | 5 | 1 | 1 | 2 | 2 | 2 | 4 | 1 | 2 | 5 |
| Depreciation | 5 | 5 | 5 | 5 | 6 | 6 | 7 | 7 | 7 | 7 | 8 | 8 | 8 |
| Profit before tax | 39 | 20 | 47 | -1 | 22 | 59 | 40 | -4 | 30 | 36 | 36 | 23 | 63 |
| Tax % | 30% | 21% | 37% | -561% | 34% | 27% | 27% | 24% | 26% | 28% | 29% | 29% | 30% |
| Net Profit | 27 | 16 | 30 | 3 | 14 | 43 | 29 | -5 | 22 | 26 | 26 | 17 | 44 |
| EPS in Rs | 2.48 | 1.33 | 2.68 | 0.32 | 1.41 | 4.05 | 2.64 | -0.87 | 1.97 | 2.31 | 2.26 | 1.47 | 4.08 |
Last Updated: August 1, 2025, 11:10 pm
Below is a detailed analysis of the quarterly data for Bliss GVS Pharma Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 207.00 Cr.. The value appears strong and on an upward trend. It has increased from 198.00 Cr. (Mar 2025) to 207.00 Cr., marking an increase of 9.00 Cr..
- For Expenses, as of Jun 2025, the value is 166.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 177.00 Cr. (Mar 2025) to 166.00 Cr., marking a decrease of 11.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 41.00 Cr.. The value appears strong and on an upward trend. It has increased from 21.00 Cr. (Mar 2025) to 41.00 Cr., marking an increase of 20.00 Cr..
- For OPM %, as of Jun 2025, the value is 20.00%. The value appears strong and on an upward trend. It has increased from 11.00% (Mar 2025) to 20.00%, marking an increase of 9.00%.
- For Other Income, as of Jun 2025, the value is 35.00 Cr.. The value appears strong and on an upward trend. It has increased from 12.00 Cr. (Mar 2025) to 35.00 Cr., marking an increase of 23.00 Cr..
- For Interest, as of Jun 2025, the value is 5.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.00 Cr. (Mar 2025) to 5.00 Cr., marking an increase of 3.00 Cr..
- For Depreciation, as of Jun 2025, the value is 8.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 8.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 63.00 Cr.. The value appears strong and on an upward trend. It has increased from 23.00 Cr. (Mar 2025) to 63.00 Cr., marking an increase of 40.00 Cr..
- For Tax %, as of Jun 2025, the value is 30.00%. The value appears to be increasing, which may not be favorable. It has increased from 29.00% (Mar 2025) to 30.00%, marking an increase of 1.00%.
- For Net Profit, as of Jun 2025, the value is 44.00 Cr.. The value appears strong and on an upward trend. It has increased from 17.00 Cr. (Mar 2025) to 44.00 Cr., marking an increase of 27.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 4.08. The value appears strong and on an upward trend. It has increased from 1.47 (Mar 2025) to 4.08, marking an increase of 2.61.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 22, 2025, 5:30 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 345 | 407 | 547 | 798 | 815 | 899 | 689 | 577 | 747 | 752 | 770 | 810 | 834 |
| Expenses | 273 | 304 | 391 | 596 | 618 | 739 | 566 | 471 | 629 | 634 | 620 | 683 | 700 |
| Operating Profit | 71 | 103 | 156 | 203 | 197 | 160 | 123 | 107 | 118 | 117 | 151 | 127 | 134 |
| OPM % | 21% | 25% | 29% | 25% | 24% | 18% | 18% | 18% | 16% | 16% | 20% | 16% | 16% |
| Other Income | 28 | 20 | 24 | 12 | -8 | 35 | 26 | 20 | -42 | 18 | -0 | 36 | 68 |
| Interest | 18 | 16 | 19 | 20 | 23 | 4 | 8 | 6 | 5 | 10 | 7 | 8 | 12 |
| Depreciation | 11 | 11 | 13 | 20 | 21 | 9 | 13 | 17 | 17 | 19 | 26 | 29 | 31 |
| Profit before tax | 71 | 96 | 148 | 175 | 145 | 182 | 129 | 104 | 54 | 106 | 117 | 126 | 159 |
| Tax % | 42% | 36% | 32% | 36% | 39% | 30% | 26% | 29% | 57% | 28% | 30% | 28% | |
| Net Profit | 41 | 61 | 100 | 113 | 89 | 127 | 95 | 74 | 23 | 77 | 82 | 90 | 112 |
| EPS in Rs | 3.97 | 5.81 | 8.00 | 7.95 | 5.70 | 11.99 | 9.43 | 6.64 | 1.45 | 6.80 | 7.21 | 8.00 | 10.12 |
| Dividend Payout % | 13% | 12% | 6% | 8% | 18% | 8% | 5% | 8% | 34% | 7% | 7% | 6% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 48.78% | 63.93% | 13.00% | -21.24% | 42.70% | -25.20% | -22.11% | -68.92% | 234.78% | 6.49% | 9.76% |
| Change in YoY Net Profit Growth (%) | 0.00% | 15.15% | -50.93% | -34.24% | 63.94% | -67.89% | 3.09% | -46.81% | 303.70% | -228.29% | 3.26% |
Bliss GVS Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 3% |
| 3 Years: | 3% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | -5% |
| 3 Years: | 44% |
| TTM: | 4% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 1% |
| 3 Years: | 24% |
| 1 Year: | 22% |
| Return on Equity | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 8% |
| 3 Years: | 9% |
| Last Year: | 8% |
Last Updated: September 5, 2025, 1:05 am
Balance Sheet
Last Updated: July 25, 2025, 3:28 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 11 |
| Reserves | 277 | 327 | 402 | 476 | 526 | 636 | 725 | 798 | 808 | 873 | 957 | 1,040 |
| Borrowings | 173 | 160 | 132 | 225 | 118 | 102 | 126 | 122 | 109 | 102 | 100 | 88 |
| Other Liabilities | 123 | 166 | 218 | 311 | 206 | 157 | 168 | 147 | 181 | 171 | 145 | 162 |
| Total Liabilities | 583 | 662 | 762 | 1,023 | 860 | 905 | 1,030 | 1,077 | 1,109 | 1,157 | 1,212 | 1,301 |
| Fixed Assets | 213 | 234 | 225 | 305 | 143 | 146 | 242 | 234 | 281 | 379 | 370 | 406 |
| CWIP | 4 | 0 | 9 | 4 | 0 | 47 | 0 | 2 | 22 | 3 | 8 | 21 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 8 | 4 | 4 |
| Other Assets | 365 | 428 | 527 | 714 | 717 | 712 | 788 | 840 | 803 | 768 | 830 | 870 |
| Total Assets | 583 | 662 | 762 | 1,023 | 860 | 905 | 1,030 | 1,077 | 1,109 | 1,157 | 1,212 | 1,301 |
Below is a detailed analysis of the balance sheet data for Bliss GVS Pharma Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 11.00 Cr.. The value appears strong and on an upward trend. It has increased from 10.00 Cr. (Mar 2024) to 11.00 Cr., marking an increase of 1.00 Cr..
- For Reserves, as of Mar 2025, the value is 1,040.00 Cr.. The value appears strong and on an upward trend. It has increased from 957.00 Cr. (Mar 2024) to 1,040.00 Cr., marking an increase of 83.00 Cr..
- For Borrowings, as of Mar 2025, the value is 88.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 100.00 Cr. (Mar 2024) to 88.00 Cr., marking a decrease of 12.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 162.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 145.00 Cr. (Mar 2024) to 162.00 Cr., marking an increase of 17.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 1,301.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,212.00 Cr. (Mar 2024) to 1,301.00 Cr., marking an increase of 89.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 406.00 Cr.. The value appears strong and on an upward trend. It has increased from 370.00 Cr. (Mar 2024) to 406.00 Cr., marking an increase of 36.00 Cr..
- For CWIP, as of Mar 2025, the value is 21.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.00 Cr. (Mar 2024) to 21.00 Cr., marking an increase of 13.00 Cr..
- For Investments, as of Mar 2025, the value is 4.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 4.00 Cr..
- For Other Assets, as of Mar 2025, the value is 870.00 Cr.. The value appears strong and on an upward trend. It has increased from 830.00 Cr. (Mar 2024) to 870.00 Cr., marking an increase of 40.00 Cr..
- For Total Assets, as of Mar 2025, the value is 1,301.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,212.00 Cr. (Mar 2024) to 1,301.00 Cr., marking an increase of 89.00 Cr..
Notably, the Reserves (1,040.00 Cr.) exceed the Borrowings (88.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -102.00 | -57.00 | 24.00 | -22.00 | 79.00 | 58.00 | -3.00 | -15.00 | 9.00 | 15.00 | 51.00 | 39.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 228 | 222 | 201 | 116 | 134 | 187 | 290 | 293 | 192 | 187 | 192 | 198 |
| Inventory Days | 70 | 69 | 55 | 50 | 55 | 46 | 64 | 110 | 116 | 94 | 113 | 111 |
| Days Payable | 176 | 165 | 153 | 100 | 55 | 47 | 75 | 82 | 86 | 79 | 58 | 63 |
| Cash Conversion Cycle | 121 | 126 | 102 | 67 | 134 | 186 | 279 | 321 | 221 | 202 | 247 | 246 |
| Working Capital Days | 86 | 105 | 84 | -10 | 135 | 154 | 232 | 264 | 179 | 192 | 207 | 199 |
| ROCE % | 20% | 23% | 31% | 29% | 27% | 26% | 18% | 12% | 14% | 12% | 14% | 12% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF | 669 | 0.07 | 0.01 | 669 | 2025-04-22 17:25:40 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 8.02 | 7.23 | 6.83 | 1.46 | 6.64 |
| Diluted EPS (Rs.) | 7.95 | 7.11 | 6.72 | 1.43 | 6.49 |
| Cash EPS (Rs.) | 11.36 | 10.31 | 9.16 | 3.90 | 8.84 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 99.68 | 95.80 | 88.08 | 81.64 | 80.27 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 99.68 | 95.80 | 88.08 | 81.64 | 80.27 |
| Revenue From Operations / Share (Rs.) | 76.85 | 73.57 | 72.16 | 72.09 | 55.96 |
| PBDIT / Share (Rs.) | 15.49 | 17.13 | 12.97 | 14.45 | 12.30 |
| PBIT / Share (Rs.) | 12.69 | 14.61 | 11.18 | 12.78 | 10.63 |
| PBT / Share (Rs.) | 11.92 | 11.16 | 10.18 | 5.22 | 10.10 |
| Net Profit / Share (Rs.) | 8.57 | 7.79 | 7.37 | 2.23 | 7.17 |
| NP After MI And SOA / Share (Rs.) | 8.00 | 7.21 | 6.80 | 1.45 | 6.64 |
| PBDIT Margin (%) | 20.15 | 23.28 | 17.97 | 20.04 | 21.98 |
| PBIT Margin (%) | 16.51 | 19.86 | 15.49 | 17.72 | 18.99 |
| PBT Margin (%) | 15.51 | 15.17 | 14.11 | 7.24 | 18.03 |
| Net Profit Margin (%) | 11.14 | 10.59 | 10.20 | 3.09 | 12.81 |
| NP After MI And SOA Margin (%) | 10.41 | 9.79 | 9.42 | 2.01 | 11.86 |
| Return on Networth / Equity (%) | 8.02 | 7.80 | 8.01 | 1.83 | 8.47 |
| Return on Capital Employeed (%) | 11.84 | 14.51 | 12.08 | 15.13 | 12.55 |
| Return On Assets (%) | 6.48 | 6.21 | 6.12 | 1.35 | 6.36 |
| Long Term Debt / Equity (X) | 0.01 | 0.03 | 0.04 | 0.02 | 0.04 |
| Total Debt / Equity (X) | 0.06 | 0.09 | 0.11 | 0.12 | 0.12 |
| Asset Turnover Ratio (%) | 0.64 | 0.64 | 0.53 | 0.59 | 0.47 |
| Current Ratio (X) | 4.81 | 5.08 | 3.61 | 3.33 | 3.76 |
| Quick Ratio (X) | 4.08 | 4.34 | 3.08 | 2.80 | 3.27 |
| Inventory Turnover Ratio (X) | 6.57 | 3.06 | 2.96 | 3.71 | 2.73 |
| Dividend Payout Ratio (NP) (%) | 6.22 | 6.90 | 7.32 | 34.41 | 7.52 |
| Dividend Payout Ratio (CP) (%) | 4.61 | 5.11 | 5.79 | 15.98 | 6.01 |
| Earning Retention Ratio (%) | 93.78 | 93.10 | 92.68 | 65.59 | 92.48 |
| Cash Earning Retention Ratio (%) | 95.39 | 94.89 | 94.21 | 84.02 | 93.99 |
| Interest Coverage Ratio (X) | 20.10 | 25.95 | 13.04 | 31.60 | 23.01 |
| Interest Coverage Ratio (Post Tax) (X) | 12.12 | 17.03 | 8.40 | 21.40 | 14.42 |
| Enterprise Value (Cr.) | 1137.76 | 1087.33 | 770.70 | 752.99 | 990.81 |
| EV / Net Operating Revenue (X) | 1.41 | 1.41 | 1.03 | 1.01 | 1.72 |
| EV / EBITDA (X) | 6.97 | 6.06 | 5.70 | 5.03 | 7.81 |
| MarketCap / Net Operating Revenue (X) | 1.53 | 1.53 | 0.98 | 1.07 | 1.76 |
| Retention Ratios (%) | 93.77 | 93.09 | 92.67 | 65.58 | 92.47 |
| Price / BV (X) | 1.18 | 1.22 | 0.83 | 0.97 | 1.26 |
| Price / Net Operating Revenue (X) | 1.53 | 1.53 | 0.98 | 1.07 | 1.76 |
| EarningsYield | 0.06 | 0.06 | 0.09 | 0.01 | 0.06 |
After reviewing the key financial ratios for Bliss GVS Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 8.02. This value is within the healthy range. It has increased from 7.23 (Mar 24) to 8.02, marking an increase of 0.79.
- For Diluted EPS (Rs.), as of Mar 25, the value is 7.95. This value is within the healthy range. It has increased from 7.11 (Mar 24) to 7.95, marking an increase of 0.84.
- For Cash EPS (Rs.), as of Mar 25, the value is 11.36. This value is within the healthy range. It has increased from 10.31 (Mar 24) to 11.36, marking an increase of 1.05.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 99.68. It has increased from 95.80 (Mar 24) to 99.68, marking an increase of 3.88.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 99.68. It has increased from 95.80 (Mar 24) to 99.68, marking an increase of 3.88.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 76.85. It has increased from 73.57 (Mar 24) to 76.85, marking an increase of 3.28.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 15.49. This value is within the healthy range. It has decreased from 17.13 (Mar 24) to 15.49, marking a decrease of 1.64.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.69. This value is within the healthy range. It has decreased from 14.61 (Mar 24) to 12.69, marking a decrease of 1.92.
- For PBT / Share (Rs.), as of Mar 25, the value is 11.92. This value is within the healthy range. It has increased from 11.16 (Mar 24) to 11.92, marking an increase of 0.76.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 8.57. This value is within the healthy range. It has increased from 7.79 (Mar 24) to 8.57, marking an increase of 0.78.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 8.00. This value is within the healthy range. It has increased from 7.21 (Mar 24) to 8.00, marking an increase of 0.79.
- For PBDIT Margin (%), as of Mar 25, the value is 20.15. This value is within the healthy range. It has decreased from 23.28 (Mar 24) to 20.15, marking a decrease of 3.13.
- For PBIT Margin (%), as of Mar 25, the value is 16.51. This value is within the healthy range. It has decreased from 19.86 (Mar 24) to 16.51, marking a decrease of 3.35.
- For PBT Margin (%), as of Mar 25, the value is 15.51. This value is within the healthy range. It has increased from 15.17 (Mar 24) to 15.51, marking an increase of 0.34.
- For Net Profit Margin (%), as of Mar 25, the value is 11.14. This value exceeds the healthy maximum of 10. It has increased from 10.59 (Mar 24) to 11.14, marking an increase of 0.55.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 10.41. This value is within the healthy range. It has increased from 9.79 (Mar 24) to 10.41, marking an increase of 0.62.
- For Return on Networth / Equity (%), as of Mar 25, the value is 8.02. This value is below the healthy minimum of 15. It has increased from 7.80 (Mar 24) to 8.02, marking an increase of 0.22.
- For Return on Capital Employeed (%), as of Mar 25, the value is 11.84. This value is within the healthy range. It has decreased from 14.51 (Mar 24) to 11.84, marking a decrease of 2.67.
- For Return On Assets (%), as of Mar 25, the value is 6.48. This value is within the healthy range. It has increased from 6.21 (Mar 24) to 6.48, marking an increase of 0.27.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 0.2. It has decreased from 0.03 (Mar 24) to 0.01, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.06. This value is within the healthy range. It has decreased from 0.09 (Mar 24) to 0.06, marking a decrease of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.64. There is no change compared to the previous period (Mar 24) which recorded 0.64.
- For Current Ratio (X), as of Mar 25, the value is 4.81. This value exceeds the healthy maximum of 3. It has decreased from 5.08 (Mar 24) to 4.81, marking a decrease of 0.27.
- For Quick Ratio (X), as of Mar 25, the value is 4.08. This value exceeds the healthy maximum of 2. It has decreased from 4.34 (Mar 24) to 4.08, marking a decrease of 0.26.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 6.57. This value is within the healthy range. It has increased from 3.06 (Mar 24) to 6.57, marking an increase of 3.51.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 6.22. This value is below the healthy minimum of 20. It has decreased from 6.90 (Mar 24) to 6.22, marking a decrease of 0.68.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 4.61. This value is below the healthy minimum of 20. It has decreased from 5.11 (Mar 24) to 4.61, marking a decrease of 0.50.
- For Earning Retention Ratio (%), as of Mar 25, the value is 93.78. This value exceeds the healthy maximum of 70. It has increased from 93.10 (Mar 24) to 93.78, marking an increase of 0.68.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 95.39. This value exceeds the healthy maximum of 70. It has increased from 94.89 (Mar 24) to 95.39, marking an increase of 0.50.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 20.10. This value is within the healthy range. It has decreased from 25.95 (Mar 24) to 20.10, marking a decrease of 5.85.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 12.12. This value is within the healthy range. It has decreased from 17.03 (Mar 24) to 12.12, marking a decrease of 4.91.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,137.76. It has increased from 1,087.33 (Mar 24) to 1,137.76, marking an increase of 50.43.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.41. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.41.
- For EV / EBITDA (X), as of Mar 25, the value is 6.97. This value is within the healthy range. It has increased from 6.06 (Mar 24) to 6.97, marking an increase of 0.91.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.53. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.53.
- For Retention Ratios (%), as of Mar 25, the value is 93.77. This value exceeds the healthy maximum of 70. It has increased from 93.09 (Mar 24) to 93.77, marking an increase of 0.68.
- For Price / BV (X), as of Mar 25, the value is 1.18. This value is within the healthy range. It has decreased from 1.22 (Mar 24) to 1.18, marking a decrease of 0.04.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.53. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.53.
- For EarningsYield, as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.06.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Bliss GVS Pharma Ltd:
- Net Profit Margin: 11.14%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 11.84% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 8.02% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 12.12
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 4.08
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 15.1 (Industry average Stock P/E: 50.47)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.06
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 11.14%
About the Company - Qualitative Analysis
Bliss GVS Pharma Ltd. is a Public Limited Listed company incorporated on 11/12/1984 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24230MH1984PLC034771 and registration number is 034771. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 667.20 Cr. and Equity Capital is Rs. 10.54 Cr. for the Year ended 31/03/2025.
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 102, Hyde Park, Saki Vihar Road, Mumbai Maharashtra 400072 | info@blissgvs.com http://www.blissgvs.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Nandkumar K Chodankar | Chairman & Ind.Director |
| Mr. Gagan Harsh Sharma | Managing Director |
| Dr. Vibha Gagan Sharma | Whole Time Director |
| Mrs. Shruti Vishal Rao | Whole Time Director |
| Mr. Santosh L Parab | Independent Director |
| Ms. Shilpa Bhatia | Independent Woman Director |
FAQ
What is the intrinsic value of Bliss GVS Pharma Ltd?
Bliss GVS Pharma Ltd's intrinsic value (as of 19 October 2025) is 101.02 which is 33.54% lower the current market price of 152.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 1,607 Cr. market cap, FY2025-2026 high/low of 191/105, reserves of ₹1,040 Cr, and liabilities of 1,301 Cr.
What is the Market Cap of Bliss GVS Pharma Ltd?
The Market Cap of Bliss GVS Pharma Ltd is 1,607 Cr..
What is the current Stock Price of Bliss GVS Pharma Ltd as on 19 October 2025?
The current stock price of Bliss GVS Pharma Ltd as on 19 October 2025 is 152.
What is the High / Low of Bliss GVS Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Bliss GVS Pharma Ltd stocks is 191/105.
What is the Stock P/E of Bliss GVS Pharma Ltd?
The Stock P/E of Bliss GVS Pharma Ltd is 15.1.
What is the Book Value of Bliss GVS Pharma Ltd?
The Book Value of Bliss GVS Pharma Ltd is 99.7.
What is the Dividend Yield of Bliss GVS Pharma Ltd?
The Dividend Yield of Bliss GVS Pharma Ltd is 0.33 %.
What is the ROCE of Bliss GVS Pharma Ltd?
The ROCE of Bliss GVS Pharma Ltd is 11.7 %.
What is the ROE of Bliss GVS Pharma Ltd?
The ROE of Bliss GVS Pharma Ltd is 8.36 %.
What is the Face Value of Bliss GVS Pharma Ltd?
The Face Value of Bliss GVS Pharma Ltd is 1.00.